Nucor earnings beat by $0.08, revenue fell short of estimates
LONDON - GSK plc, the global biopharma company, has filed its Annual Report on Form 20-F for the year ended December 31, 2024, with the Securities and Exchange Commission (SEC). The report, which includes audited financial statements, was submitted in line with the requirements of the New York Stock Exchange Listed Company Manual Section 203.01.
The document is now accessible to the public on GSK’s website and the SEC’s official site. Additionally, shareholders will have the opportunity to receive a printed copy of the full report and the Notice of Annual General Meeting around March 24, 2025. Requests for the hard copy version can be made through GSK’s registrars in the UK, Computershare Investor Services, or the company’s ADR depositary in the US, J.P. Morgan Chase Bank, N.A. Alternatively, shareholders may contact the GSK Response Center in the USA.
GSK emphasizes its commitment to uniting science, technology, and talent in its mission to preemptively combat diseases. The company underlines the importance of considering the cautionary note regarding forward-looking statements in the report. These statements are subject to risks and uncertainties that could lead to results significantly different from those projected, as detailed under "Risk factors" in the report.
This announcement, based on a press release statement, serves to inform shareholders and the public of the availability of GSK’s financial information for the past year. It reflects the company’s dedication to transparency and adherence to regulatory requirements for listed companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.